MX2024002684A - Metodos para la prevencion y tratamiento de sinucleinopatias. - Google Patents
Metodos para la prevencion y tratamiento de sinucleinopatias.Info
- Publication number
- MX2024002684A MX2024002684A MX2024002684A MX2024002684A MX2024002684A MX 2024002684 A MX2024002684 A MX 2024002684A MX 2024002684 A MX2024002684 A MX 2024002684A MX 2024002684 A MX2024002684 A MX 2024002684A MX 2024002684 A MX2024002684 A MX 2024002684A
- Authority
- MX
- Mexico
- Prior art keywords
- synucleinopathies
- methods
- prevention
- treatment
- compositions
- Prior art date
Links
- 208000032859 Synucleinopathies Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163239505P | 2021-09-01 | 2021-09-01 | |
| PCT/US2022/075836 WO2023034914A2 (en) | 2021-09-01 | 2022-09-01 | Methods for the prevention and treatment of synucleinopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024002684A true MX2024002684A (es) | 2024-05-16 |
Family
ID=85413127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002684A MX2024002684A (es) | 2021-09-01 | 2022-09-01 | Metodos para la prevencion y tratamiento de sinucleinopatias. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240358806A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4395894A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024534901A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240055785A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118119403A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022337284A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3230300A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024002684A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202323275A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023034914A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025137102A1 (en) * | 2023-12-18 | 2025-06-26 | Vaxxinity, Inc. | Peptide immunogen compositions and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6906169B2 (en) * | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
| EP1572894B1 (en) * | 2001-11-21 | 2016-04-13 | New York University | Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto |
| US8697082B2 (en) * | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| GB201512203D0 (en) * | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| JP2021508672A (ja) * | 2017-06-16 | 2021-03-11 | ユナイテッド ニューロサイエンスUnited Neuroscience | シヌクレイノパチーの治療のためのアルファ−シヌクレインタンパク質のc末端からのペプチド免疫原及びその製剤 |
-
2022
- 2022-09-01 KR KR1020247010060A patent/KR20240055785A/ko active Pending
- 2022-09-01 US US18/688,196 patent/US20240358806A1/en active Pending
- 2022-09-01 AU AU2022337284A patent/AU2022337284A1/en active Pending
- 2022-09-01 EP EP22865800.1A patent/EP4395894A4/en active Pending
- 2022-09-01 TW TW111133232A patent/TW202323275A/zh unknown
- 2022-09-01 WO PCT/US2022/075836 patent/WO2023034914A2/en not_active Ceased
- 2022-09-01 CA CA3230300A patent/CA3230300A1/en active Pending
- 2022-09-01 CN CN202280070314.1A patent/CN118119403A/zh active Pending
- 2022-09-01 JP JP2024514038A patent/JP2024534901A/ja active Pending
- 2022-09-01 MX MX2024002684A patent/MX2024002684A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022337284A1 (en) | 2024-03-21 |
| US20240358806A1 (en) | 2024-10-31 |
| TW202323275A (zh) | 2023-06-16 |
| KR20240055785A (ko) | 2024-04-29 |
| EP4395894A4 (en) | 2025-08-06 |
| CA3230300A1 (en) | 2023-03-09 |
| WO2023034914A3 (en) | 2023-04-13 |
| CN118119403A (zh) | 2024-05-31 |
| EP4395894A2 (en) | 2024-07-10 |
| JP2024534901A (ja) | 2024-09-26 |
| WO2023034914A2 (en) | 2023-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023012245A (es) | Compuestos, composiciones y metodos para el tratamiento del cancer. | |
| MY206478A (en) | Inhibitors of sarm1 | |
| MY205416A (en) | Tyk2 inhibitors and uses thereof | |
| ZA202301801B (en) | Inhibitors of sarm1 | |
| MX2024001243A (es) | Composiciones y metodos para el tratamiento de melanoma. | |
| MX2021011488A (es) | Compuestos y usos de estos. | |
| MX2024004993A (es) | Agentes degradantes de la proteina tirosina cinasa 2 (tyk2) y usos de los mismos. | |
| MX2022015753A (es) | Metodos y composiciones para tratamiento de epidermolisis ampollosa. | |
| MX2023015021A (es) | Mimeticos de hepcidina para el tratamiento de la hemocromatosis hereditaria. | |
| MX2020011344A (es) | Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios. | |
| SA522431538B1 (ar) | طُرق وتركيبات لعلاج تساقط الشعر | |
| PH12022550130A1 (en) | Enzyme inhibitors | |
| WO2022020353A3 (en) | Methods and compositions for treatment and prevention of coronavirus infection | |
| MX2021004819A (es) | Composiciones y metodos para tratar lesiones cerebrales. | |
| PH12022550118A1 (en) | Enzyme inhibitors | |
| EP4225923A4 (en) | COMPOSITIONS AND METHODS FOR PREVENTING AND/OR TREATING COVID-19 | |
| PH12022550114A1 (en) | Methods of treating or preventing spinal muscular atrophy | |
| IL312583A (en) | A preparation for the treatment and prevention of COVID-19 | |
| MX2025001279A (es) | Aril-triazolilo y antagonistas gpr84 relacionados y usos de estos | |
| PH12021552499A1 (en) | Methods for the treatment of beta-thalassemia | |
| WO2023034914A3 (en) | Methods for the prevention and treatment of synucleinopathies | |
| MX2025004758A (es) | Compuestos y su uso para el tratamiento de hemoglobinopatias | |
| MX2023004881A (es) | Inhibidores de pde9 para el tratamiento de insuficiencia cardíaca. | |
| WO2020185651A3 (en) | Compositions and methods for treating huntington's disease | |
| MX2022013883A (es) | Compuestos de metiltioninio para uso en el tratamiento de covid-19. |